These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23552468)

  • 1. The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer.
    Arlt A; Schäfer H; Kalthoff H
    Oncogenesis; 2012 Nov; 1(11):e35. PubMed ID: 23552468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells.
    Geismann C; Grohmann F; Sebens S; Wirths G; Dreher A; Häsler R; Rosenstiel P; Hauser C; Egberts JH; Trauzold A; Schneider G; Sipos B; Zeissig S; Schreiber S; Schäfer H; Arlt A
    Cell Death Dis; 2014 Oct; 5(10):e1455. PubMed ID: 25299780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical role of NF-κB in pancreatic cancer.
    Prabhu L; Mundade R; Korc M; Loehrer PJ; Lu T
    Oncotarget; 2014 Nov; 5(22):10969-75. PubMed ID: 25473891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer.
    Pramanik KC; Makena MR; Bhowmick K; Pandey MK
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Zhang D; Li L; Jiang H; Knolhoff BL; Lockhart AC; Wang-Gillam A; DeNardo DG; Ruzinova MB; Lim KH
    Clin Cancer Res; 2017 Apr; 23(7):1748-1759. PubMed ID: 27702822
    [No Abstract]   [Full Text] [Related]  

  • 6. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer.
    Geismann C; Grohmann F; Dreher A; Häsler R; Rosenstiel P; Legler K; Hauser C; Egberts JH; Sipos B; Schreiber S; Linkermann A; Hassan Z; Schneider G; Schäfer H; Arlt A
    Biochim Biophys Acta Mol Cell Res; 2017 May; 1864(5):782-796. PubMed ID: 28188806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.
    Kha ML; Hesse L; Deisinger F; Sipos B; Röcken C; Arlt A; Sebens S; Helm O; Schäfer H
    Oncogene; 2019 Feb; 38(9):1461-1476. PubMed ID: 30302023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting apoptosis pathways in pancreatic cancer.
    Arlt A; Müerköster SS; Schäfer H
    Cancer Lett; 2013 May; 332(2):346-58. PubMed ID: 21078544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-β1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-β1.
    Genrich G; Kruppa M; Lenk L; Helm O; Broich A; Freitag-Wolf S; Röcken C; Sipos B; Schäfer H; Sebens S
    BMC Cancer; 2016 Feb; 16():155. PubMed ID: 26915435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer.
    Yang J; Liu DJ; Zheng JH; He RZ; Xu DP; Yang MW; Yao HF; Fu XL; Yang JY; Huo YM; Tao LY; Hua R; Sun YW; Kong XM; Jiang SH; Liu W
    Cell Oncol (Dordr); 2022 Jun; 45(3):367-379. PubMed ID: 35486320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
    Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
    Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma.
    Wang Y; Wang D; Dai Y; Kong X; Zhu X; Fan Y; Wang Y; Wu H; Jin J; Yao W; Gao J; Wang K; Xu H
    Front Oncol; 2021; 11():652283. PubMed ID: 34046348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
    Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
    Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
    Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
    Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
    Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
    J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance.
    Meng Q; Liang C; Hua J; Zhang B; Liu J; Zhang Y; Wei M; Yu X; Xu J; Shi S
    Theranostics; 2020; 10(9):3967-3979. PubMed ID: 32226532
    [No Abstract]   [Full Text] [Related]  

  • 18. YEATS2 regulates the activation of TAK1/NF-κB pathway and is critical for pancreatic ductal adenocarcinoma cell survival.
    Sheng H; Zheng F; Lan T; Chen HF; Xu CY; Wang SW; Weng YY; Xu LF; Zhang F
    Cell Biol Toxicol; 2023 Jun; 39(3):1-16. PubMed ID: 34686948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
    Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
    Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.